TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of resistance-preventing precision therapies to patients with cancer. Their proprietary drug discovery engine enables the identification of novel drug resistance regulators and the development of small molecule therapies against these promising drug targets. TOLREMO’s therapies aim to complement standard cancer therapies to offer better response rates, longer survival and improved quality of life.

info@tolremo.com | tolremo.com